BIIB080, an ASO that targets human MAPT gene to prevent tau protein production for tauopathies including AD, has reported positive phase 1b results with evidence for tau reduction in the CSF of treated patients with mild AD (Mummery et al., 2021) and is in currently in Phase 2 trial in early Alzheimer’s Disease (NCT05399888). Here, MAPT is linked to Alzheimer disease.